These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15308347)

  • 1. Reactogenicity of acellular pertussis vaccine in 4-year-olds in The Netherlands.
    Keijzer-Veen MG; Holty-van der Wekken L; Juttmann RE; de Groot R; Rümke HC
    Vaccine; 2004 Sep; 22(25-26):3256-7. PubMed ID: 15308347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events following booster doses of diphtheria-tetanus-inactivated poliovirus and acellular pertussis vaccines for 4-year-old children in The Netherlands.
    Bults M; Kemmeren JM; van der Maas NA
    Vaccine; 2007 Jul; 25(29):5272-7. PubMed ID: 17573165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands.
    David S; Vermeer-de Bondt PE; van der Maas NA
    Vaccine; 2008 Oct; 26(46):5883-7. PubMed ID: 18775463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?
    Halperin SA; Sweet L; Baxendale D; Neatby A; Rykers P; Smith B; Zelman M; Maus D; Lavigne P; Decker MD
    Pediatr Infect Dis J; 2006 Mar; 25(3):195-200. PubMed ID: 16511379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
    Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
    Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Increase in localised symptoms in 4-year-olds following revaccination with DaPT-IPV].
    David S; Vermeer-de Bondt P; van der Maas N
    Ned Tijdschr Geneeskd; 2010; 154():A980. PubMed ID: 20456777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.
    Halperin SA; Tapiero B; Law B; Diaz-Mitoma F; Duval B; Langley JM; Elrick DB; Jacquet JM
    Vaccine; 2006 May; 24(18):4017-23. PubMed ID: 16516357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and reactogenicity of a low dose diphtheria tetanus acellular pertussis vaccine (Boostrix) in pre-school Indian children.
    Bose A; Dubey AP; Gandhi D; Pandit A; Raghu MB; Raghupathy P; Rao MI; Verghese VP; Datta SK; Bock HL
    Indian Pediatr; 2007 Jun; 44(6):421-4. PubMed ID: 17620694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
    J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years.
    Marshall H; Nolan T; Roberton D; Richmond P; Lambert S; Jacquet JM; Schuerman L
    Vaccine; 2006 Aug; 24(35-36):6120-8. PubMed ID: 16822597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
    Chan SH; Tan PT; Han HH; Bock HL
    Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective assessment of the effect of needle length and injection site on the risk of local reactions to the fifth diphtheria-tetanus-acellular pertussis vaccination.
    Jackson LA; Starkovich P; Dunstan M; Yu O; Nelson J; Dunn J; Rees T; Zavitkovsky A; Maus D; Froeschle JE; Decker M
    Pediatrics; 2008 Mar; 121(3):e646-52. PubMed ID: 18310184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the risk of pertussis in newborn infants.
    Blangiardi F; Ferrera G
    J Prev Med Hyg; 2009 Dec; 50(4):206-16. PubMed ID: 20812515
    [No Abstract]   [Full Text] [Related]  

  • 20. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.